Technical Analysis for DCTH - Delcath Systems, Inc.

Grade Last Price % Change Price Change
F 12.39 -2.21% -0.28
DCTH closed down 3.28 percent on Thursday, April 15, 2021, on 68 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical DCTH trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness -1.46%
Wide Bands Range Expansion -1.46%
Oversold Stochastic Weakness -1.46%
Narrow Range Bar Range Contraction -4.69%
NR7 Range Contraction -4.69%
Doji - Bullish? Reversal -4.69%
Wide Bands Range Expansion -4.69%
Narrow Range Bar Range Contraction -3.44%
Wide Bands Range Expansion -3.44%
New Downtrend Bearish -3.22%
Older End-of-Day Signals for DCTH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 33 minutes ago
60 Minute Opening Range Breakdown about 2 hours ago
Down 1% about 2 hours ago
Up 1% about 4 hours ago
Down 5% about 24 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Development Oncology Chemotherapy Chloride Melanoma Carcinoma Specialty Drugs Hepatology Infectious Causes Of Cancer Liver Cancer Investigational Products Ocular Melanoma Cholangiocarcinoma Liver Cancers

Is DCTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.18
52 Week Low 6.06
Average Volume 325,260
200-Day Moving Average 14.30
50-Day Moving Average 18.05
20-Day Moving Average 15.17
10-Day Moving Average 13.42
Average True Range 1.37
ADX 29.07
+DI 10.69
-DI 28.24
Chandelier Exit (Long, 3 ATRs ) 16.19
Chandelier Exit (Short, 3 ATRs ) 15.80
Upper Bollinger Band 19.61
Lower Bollinger Band 10.74
Percent B (%b) 0.22
BandWidth 58.47
MACD Line -1.48
MACD Signal Line -1.34
MACD Histogram -0.137
Fundamentals Value
Market Cap 52.16 Million
Num Shares 4.12 Million
EPS -1.84
Price-to-Earnings (P/E) Ratio -6.89
Price-to-Sales 15.56
Price-to-Book 20.09
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.37
Resistance 3 (R3) 14.39 13.84 14.08
Resistance 2 (R2) 13.84 13.41 13.83 13.99
Resistance 1 (R1) 13.26 13.14 12.99 13.24 13.89
Pivot Point 12.71 12.71 12.58 12.70 12.71
Support 1 (S1) 12.13 12.28 11.86 12.11 11.45
Support 2 (S2) 11.58 12.01 11.57 11.35
Support 3 (S3) 11.00 11.58 11.26
Support 4 (S4) 10.98